VP, DIRECTOR OF MINING SERVICES, FORSGREN ASSOCIATES
"The changing regulatory environment, pressure to streamline the permitting process, and significant investment coming into the state are all driving real-time planning, creative strategies, and good organization."
VICE PRESIDENT AND GENERAL MANAGER - BALD MOUNTAIN, KINROSS GOLD CORPORATION
"Interestingly, despite increasingly challenging operating environments, the industry’s ounce production continues to maintain or improve. That speaks to the creativeness and technical expertise of the whole value chain of the industry."
EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."
"We believe that the successful chemical distributor of the future needs to be truly digital and Pochteca is investing heavily to be at the forefront of this trend."
"In 2023, we anticipate growing our market reach by double-digits and developing new products, which will be largely driven by the expansion of the Mexican market, as well as our focus on bolstering the paper, mining, and agriculture sector through the use of our products."
CEO AT MMC OIL AND GAS ENGINEERING & PARTNER TO DORIS MMC SDN BHD
"We are the only tier-one, premier design engineering consultancy company that is fully local, amidst other established internationally known design engineering consultant houses."
"The conversation in the mining industry primarily revolves around the royalties bill, but to discuss reforms, we need to put everything on the table, including labor, pensions, and health."
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.